Harvey Jones isn't having much fun playing the GSK share price game. The FTSE 100 pharmaceutical stock must work hard to make ...

Pharmaceutical giant GSK and the University of Oxford are creating a new cancer vaccine to prevent the disease from ...

GSK PLC GSK shares advanced 3.35% to £14.02 Monday, on what proved to be an all-around great trading session for the stock ...

Fifth Third Bancorp reduced its position in GSK plc (NYSE:GSK – Free Report) by 61.3% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 4,887 shares of the ...

GSK plc has announced that new drug applications have been accepted for review by the China National Medical Products ...

GSK PLC closed 23.91% below its 52-week high of £18.24, which the company reached on May 16th.

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Jemperli (dostarlimab) in combination with chemotherapy (carboplatin and paclitaxel) for first-line treatment of adult ...

The age of targeted cancer therapies brings the potential for more treatment options, greater effectiveness and fewer side effects.

GSK (GSK) stock in focus as its experimental drug depemokimab undergoes EU review for asthma and nasal polyps. Read more here ...

Learn More. If the GSK (LSE: GSK) share price was a video game, it would be flashing GAME OVER to me right now. Shares in the pharmaceutical giant started 2025 trading at a 12-month low.